A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer

Trial Profile

A phase II trial of docetaxel plus carboplatin plus bevacizumab as neoadjuvant therapy for triple negative breast cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Carboplatin (Primary) ; Docetaxel (Primary)
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jan 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top